Is Celldex Therapeutics (CLDX) Headed for a Breakout?

Celldex Therapeutics Inc. (CLDX) is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer…

Over the summer Celldex Therapeutics Inc. (CLDX) reported strong results from an early-stage study for its experimental antibody therapy CDX-0159. Then last month, the company announced that it had initiated dosing in the first cohort of a phase I study evaluating the drug.

The company appears to have a solid balance sheet as it had $164 million in cash at the end of the last quarter compared to only $1 million in long-term debt. In terms of growth, sales are up 90.7% over the past year and are expected to soar 212.8% year over year in the current quarter leading to a Growth Grade of B in our POWR Ratings system.

However, the stock looks overvalued with a price-to-sales ratio of 234.98, which is well above the high industry average of 12.7. The stock has been showing bullish long-term momentum as shown in the chart below.

Take a look at the 1-year chart of CLDX below with my added notations…

See chart and continue reading at STOCKNEWS.com